FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL												
OMB Number:	3235-0287											
Estimated average burden												
hours per response:	0.5											

	Check this box if no longer subject to							
\neg	Section 16. Form 4 or Form 5							
_	obligations may continue. See							
	Instruction 1(b).							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RAYNOR DANIEL						2. Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ANIP]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
														X				10% (
(Last) C/O ANI	(Fi	rst) (CEUTICALS, II	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/14/2014									belo	er (give title w)	;	Other (specify below)		
210 MAIN STREET WEST					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BAUDET	ГТЕ М	N 5	56623		_									X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(St	ate) (.	Zip)																	
		Tabl	e I - N	on-Deri	ative	Seci	uritie	s Ac	quire	d, Di	sposed o	f, or B	enefic	ially	Owne	ed				
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/Y						Execution Date,		ate,	3. Transaction Code (Instr. 8) 4. Securities Disposed Of					nd 5) Securit Benefic		ies ially Following	Form (D) o	n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s)			(msu. 4)	
Common Stock 03/14/20				2014	14			S		12,347	D	\$33.8	52		4,182		T I	See Footnote ⁽²⁾		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Day/\(\text{(Month/Day/\)}\)		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		De Se (In:	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares							

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.53 to \$34.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by him at each separate price on each date of sale.
- 2. These shares are held by Argentum Capital Partners II, L.P. (ACP II). Argentum Investments, LLC is the managing member of Argentum Partners II, LLC, which is the general partner of ACP II. Daniel Raynor is a co-managing member of Argentum Investments, LLC. Mr. Raynor disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. The business address of ACP II is 60 Madison Avenue, Suite 701, New York, NY 10010.

03/18/2014 /s/ Daniel Raynor

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.